Casper stocks jumped 30 percent following its IPO on Wednesday morning, ultimately closing up on the day, despite a chorus of doubts from investors who questioned the online mattress seller's underlying profitability.

Skepticism ratcheted up in recent days as Casper lowered its starting price from $17 to $12 per share — the bottom end of its expected range and a signal to investors that the company was bracing itself for a less than stellar opening on the stock market.

Either price is a far cry from the $1.1 billion valuation that Casper received as a private company in March 2019 after another round of venture capital.

But the slight pop in stock value is no cause for celebration, according to Sucharita Kodali, a retail analyst for Forrester.

"The numbers for Casper don't look terribly impressive right now," Kodali told Cheddar. "It's not been improving from a profitability standpoint."

For the last quarter, the company reported a net loss of $67.3 million on $312.3 million in revenue. Heavy marketing costs and a generous 100-day return policy have also given investors pause.

Kodali said the IPO does not bode well for the direct-to-consumer space, which has become saturated with venture capitalists eager for an exit through either an acquisition or public markets.

The botched IPO of WeWork — another company with a more straightforward business model than its Silicon Valley trappings might suggest — has served as a cautionary tale for investors.

"I think the industry has been so skeptical towards these companies that call themselves tech startups," she said. "I think investors are becoming wizened to the fact that these are often VC-inflated stories."

Not quite a tech company but not content to be a simple mattress seller, Casper in recent years has expanded into what it calls the "sleep economy," encompassing bed-sheets, bed-frames, pillows, dog mats, and even CBD gummies for sleep aid.

"Casper tried to make a darn good case that it was more than just mattresses," Kodali said. "They tried to brand this whole vision of the sleep economy, but the truth is that its bread and butter is a mattress in a box and that is fundamentally what everyone sees them as."

But even competing on those terms has gotten more difficult. Since Casper launched in 2014, a number of competitors have adopted the mattress-in-a-box concept, including Nectar, Helix, Ghostbed, Purple, and Allswell, some of them at lower price points.

As the novelty of getting an entire mattress delivered in a box fades, Casper could face some difficult adjustments to the size and scope of its operation.

"You have to cut staff and you have to cut marketing, unfortunately, and that is the only path to profitability that these companies have," Kodali said.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More